From: RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
Hazard Ratio
95% CI
P value
Age (< 60 vs > 60) **
1.81
1.21–2.70
0.004
Stage (II vs III and IV) **
2.14
1.47–2.12
< 0.001
TMB**
0.93
0.89–0.98
0.007
No. DDR genes mutated
1.02
0.91–1.13
0.77
Sex
1.07
0.76–1.49
0.71